TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05818423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Health Academy
Description: The Brain Health Academy group will review online content about brain health (1 hour, 2 days/week for 12 weeks) and will complete a brief survey after each module to assess compliance (30 hours total).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Health Together
Description: The Brain Health Together group will participate in online, live-streaming, group-based Moving Together classes (1 hour/week); Brain Health education group classes (1 hour/week) and individual brain health coaching sessions (0.5 hours/week) for 12 weeks (30 hours total).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maintain Brain Health Together
Description: The Maintaining Brain Health Together group will participate in the full Brain Health Together program (30 hours) for 12 weeks followed by weekly group classes and six individual coaching for an additional 12 weeks (additional 15 hours).
Study: NCT04777071

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT scan
Study: NCT05645029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glass ionomer-chlorhexidine
Description: chlorhexidine will be added to glass ionomer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glass ionomer-titanium dioxide powder
Description: titanium dioxide will be added to glass ionomer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: glass ionomer
Description: glass ionomer will be used without any additives
Study: NCT05427825

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERAS anesthetic care
Description: The ERAS anesthetic care includes EEG spectrum-guided multimodal anesthesia and HPI-guided hemodynamic therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard anesthetic care
Description: The standard anesthetic care includes bispectral index guided general anesthesia and arterial line monitored hemodynamic care.
Study: NCT05155696

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Kefir probiotic drink (supplied by Nourish)
Description: 125ml per day of dairy based probiotic drink (Kefir) containing ≥ 50billion colony forming units (CFU), supplied in plain packaging.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: 125ml of non-fermented dairy based placebo (UHT milk) per day, supplied in plain packaging.
Study: NCT04777071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 Gozetotide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo PET/MR scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study: NCT06180148

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical insufflator-exsufflator
Description: In the active comparator group a mechanical insufflator-exsufflator will be used in the postoperative period 6 and 24 hours after extubation as follows (coughing maneuver): application of inspiratory pressure of 40-70 cm of water (the minimum value to achieve a peak cough flow of 300 l/min) for 2 seconds with the subsequent creation of an expiratory vacuum of -40 cm of water within 2 seconds. During inhalation and exhalation, the patient will apply oscillations with a frequency of 10 Hz and an amplitude of 10 cm of water. A series of 10 such maneuvers will be used, with a pause of a few seconds to ensure patient comfort. The coughing maneuver will be performed through an oronasal mask tightly pressed to the face.
Study: NCT04527016

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microbiota and eosinophils based therapy
Description: 1. Blood eosinophils ≥3%+ mixed airway microbiota: 3 month course of FP 50 ug twice daily via spacer~2. Blood eosinophils\<3%+ Moraxella species\>40% in airway microbiota: Azithromycin 10mg/kg per day for 3 consecutive days a week for 4 weeks;~3. Blood eosinophils ≥3%+ Moraxella species\>40% in airway microbiota: 3 month course of FP 50 ug twice daily via spacer and Azithromycin 10mg/kg per day for 3 consecutive days a week for 4 weeks;~4. Blood eosinophils\<3%+ mixed airway microbiota: intermittent budesonide inhalation suspension (1mg twice daily) and terbutaline inhalation suspension for 7 days during wheeze episode.~The participants will be followed up for one year after the intervention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clinical guidelines based therapy
Description: The children will be treated as directed by their paediatrician ( The clinical practice is based on the guideline for the diagnosis and optimal management of asthma in children of China 2016).The treatment protocols include:~1. regular inhaled FP 50 ug twice daily via spacer for 3 months;~2. montelukast(4mg od for 3 months)~3. intermittent budesonide inhalation suspension (1mg twice daily for 7 days during wheeze episode).~The participants will be followed up for one year after the intervention.
Study: NCT05359939

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 18F-FDGal PET/CT versus 18F-choline PET/CT
Description: Fifty patients with known HCC are investigated with two PET/CT-scans with 18F-FDGal and 18F-choline. In some of the cases one of the CT-scans will be altered to a contrast-enhanced MRI scan. A contrast-enhanced CT scan will be performed as part of the standard diagnostic work-up. We include patients with known HCC as the aim is to compare the diagnostic performance of the two tracers. Images will be analyzed for focal lesions and compared to other modalities by an experienced specialist in PET and an experienced radiologist.
Study: NCT06552585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12-weeks weight prevention program
Description: Twice a week, over 12-weeks, the weight program group carried out a strength program with the 5 open kinetic chain exercises most often reported in the literature to prevent swimmer's shoulder - internal rotation at 90°, external rotation at 90°, scapular punches, T's, and Y's - with two weights Domyos with 1, 2, 3, 4, or 5 kg.The load used to perform the programs with weights were previously assessed and adjusted for each swimmer, corresponding to 75% of one repetition maximum. After 6 weeks of program execution, each swimmer carried out another one repetition maximum test assessment, to verify the possibility of a load instrument progression.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12-weeks elastic band prevention program
Description: Twice a week, over 12-weeks, the elastic band program group carried out a strength program with the 5 open kinetic chain exercises most often reported in the literature to prevent swimmer's shoulder - internal rotation at 90°, external rotation at 90°, scapular punches, T's, and Y's - with an elastic band Bodytone Power Band with 10, 15, 20, 25, or 30 kg weights Domyos.The load used to perform the programs with weights were previously assessed and adjusted for each swimmer, corresponding to 75% of one repetition maximum. After 6 weeks of program execution, each swimmer carried out another one repetition maximum test assessment, to verify the possibility of a load instrument progression.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham intervention
Description: The control group performed a sham intervention, twice a week, for 12-weeks. This intervention consisted of 2 sets of 10 repetitions of 5 shoulder mobility exercises, without preventive aim, normally carried out in warm-up before training: shoulder maximum flexion and extension, horizontal abduction and adduction starting from 90º of shoulder abduction, maximum internal/external rotation starting from 90º of shoulder abduction, circumduction of the shoulder in a clockwise direction and circumduction of the shoulder in a counterclockwise direction. There was no progression after 6-weeks of this sham intervention. The coach of the respective team checked the execution of the exercises, but there was no individualized monitoring with a regular exercise technique correction by a physiotherapist.
Study: NCT06552520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQH2722 injection
Description: Humanized interleukin-4 receptor alpha (4Rα) monoclonal antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of TQH2722 injection
Description: Placebo without drug substance
Study: NCT04928157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure (PAP)
Description: A device used with a nose or face mask which delivers airflow/pressure into the airway, holding the airway open and keeping it from collapsing. Device will be used for 8 weeks.
Study: NCT06091436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GenSci094
Description: On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg or 100μg (0.5 mL) GenSci094 was administered in the abdominal wall.
Study: NCT05126368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: During cataract surgery the Eyhance toric II intraocular lens will be implanted in one eye of the patient
Study: NCT06091436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo RecFSH / follitropin alfa
Description: powder-injection, but without the active ingedient, SC injection . Daily SC injections were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
Study: NCT06296628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miraπ
Description: This device has tiny sensors that measure the movement of the healthy fingers and tiny motors that move the affected fingers of the patient.~The device is connected to a specially designed finger mechanism that moves the affected fingers of the patient. This opening mechanism is designed in a way that it prevents the fingers from being forced into any hurting position. If the patient moves the healthy fingers during training, also the fingers of the affected hand are moved by the device at the same time. This creates the effect of mirror therapy for the brain as the patient can see both hands moving.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mirror Therapy
Description: Current standard of care using MT.
Study: NCT06091436

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Biological: RecFSH / Follitropin alfa (Days 1 to 7)
Description: Daily SC injections with 150IU or 225IU recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
Study: NCT06533540

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TPX-115(allogeneic fibroblasts)
Description: Intradermal injection of TPX-115(allogeneic fibroblasts)
Study: NCT06091436

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo GenSci094
Description: Pre-filled syringe containing an identical solution when compared to GenSci094. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.
Study: NCT06533540

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TPX-115(allogeneic fibroblasts)
Description: Intradermal injection of TPX-115(allogeneic fibroblasts)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TPX-115(allogeneic fibroblasts)
Description: Intradermal injection of TPX-115(allogeneic fibroblasts)
Study: NCT04510194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin; immediate release formation; 500mg on Day 1; 500mg BID on Day 2 through Day 5; 500mg in AM and 1,000mg in PM on Day 6 through Day 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin; immediate release formation; 500mg on Day 1; 500mg BID on Day 2 through Day 5; 500mg in AM and 1,000mg in PM on Day 6 through Day 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin; immediate release formation; 500mg on Day 1; 500mg BID on Day 2 through Day 5; 500mg in AM and 1,000mg in PM on Day 6 through Day 14.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo; appearance and size are exact matching to the three study drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: An antidepressant, administered 50mg per day on Day 1; then 50mg twice-daily for Day 2 through Day 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: An antidepressant, administered 50mg per day on Day 1; then 50mg twice-daily for Day 2 through Day 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: An anti-parasitic medication administered as 390mcg/kg to 470mcg/kg per day for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: An anti-parasitic medication administered as 390mcg/kg to 470mcg/kg per day for 3 days
Study: NCT06156384

Intervention type: DEVICE
Intervention: FITBONE® Lengthening Nail
Description: The patient is installed on a standard orthopaedic table, intramedullary reaming is performed through a metal working tube. The osteotomy is performed percutaneously and then an osteotome according to the postage-stamp technique. Once the FITBONE lengthening nail is placed in the desired location, it should be connected to the subcutaneous receiver. The receiver should be placed close enough to the skin surface to ensure the energy transfer from the external transmitter.~After 5 to 10 days after surgery, the lengthening mechanism is operated by the patient, using the transmitter. An elongation of approximately 1 mm/day takes place. The attending physician determines the rhythm of lengthening in each case. When the desired elongation length is reached, the consolidation phase begins, which is necessary for bone regeneration. The FITBONE lengthening nail can be removed once the bone has consolidated, approximately one to one and a half years after implantation.
Study: NCT05046314

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TK216+Vincristin
Description: TK216 was continuously administered for 14 days，then rest for 14 days. Vincristin is given before TK216 only in the first day of each cycle, the first cycle of VCR is 0.75mg/m\^2 and 1.5mg/m\^2 from the second cycle，every 28 days is a study cycle.
Study: NCT05995717

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PKU UP
Description: PKU UP is a food for special medical purposes (FSMP). This product is for use in the dietary management of Phenylketonuria (PKU) in children aged from one (1) to ten (10) years.~PKU UP is a neutral-flavoured, ready-to-drink, low-phenylalanine protein substitute containing a blend of glycomacropeptide (GMP) isolate, essential and non-essential amino acids, fat, carbohydrate, vitamins, minerals and docosahexaenoic acid (DHA).
Study: NCT06563609

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive physical Therapy
Description: Tailored exercise programs supervised by trained physiotherapists, focusing on improving cardiorespiratory fitness, strength, and functional capacity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive physical Therapy
Description: Tailored exercise programs supervised by trained physiotherapists, focusing on improving cardiorespiratory fitness, strength, and functional capacity.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic treatment
Description: Administration of probiotic yeast Saccharomyces boulardii twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic treatment
Description: Administration of probiotic yeast Saccharomyces boulardii twice daily

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individualised Nutritional Support
Description: Personalized nutritional plans guided by a dietitian, addressing malnutrition and caloric/protein deficiencies with daily caloric intake adjustments and supplements if necessary based on the EFFORT trial.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individualised Nutritional Support
Description: Personalized nutritional plans guided by a dietitian, addressing malnutrition and caloric/protein deficiencies with daily caloric intake adjustments and supplements if necessary based on the EFFORT trial.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard hospital care
Description: Patients will receive standard hospital care
Study: NCT04670965

Intervention type: BIOLOGICAL
Intervention: E-PRF/rhBMP-2 (similar ratios)
Description: During its preparation, 1.5 mg/ml rhBMP-2 will be incorporated into standardized samples to assure similar E-PRF to rhBMP-2 ratios. To allow for consistency across all samples, standardized E-PRF volume will be established using formation templates. Following its preparation, the E-PRF/rhBMP2 scaffold will undergo a standard in vitro assay to investigate growth factor release over time (ELISA quantification assay). Briefly, the e-PRF/rhBMP2 scaffold will be placed in a shaking incubator at 37 degree Celsius and assessed for growth factor release of rhBMP-2 over time.

Intervention type: BIOLOGICAL
Intervention: E-PRF/ACS/rhBMP-2
Description: rhBMP-2 diluted to account for the additional volume from the E-PRF in other samples will be loaded onto lyophilized absorbable collagen sponges as per the package insert. After the addition of the rhBMP-2, the ACS will be cut into 2mm x 2mm pieces and incorporated into the E-PRF membrane. Following its preparation, rhBMP-2 release from the E-PRF/ACS/rhBMP2 scaffold will be quantified using the ELISA quantification assay as described above.

Intervention type: BIOLOGICAL
Intervention: rhBMP-2/E-PRF
Description: rhBMP-2 diluted to account for the additional volume from the E-PRF in other samples will be loaded onto lyophilized absorbable collagen sponges as per the package insert. Rh-BMP2 release will be quantified using the ELISA quantification assay as described above

Intervention type: BIOLOGICAL
Intervention: E-PRF only
Description: E-PRF will be prepared and standardized, but no rhBMP-2 will be added to the material. After preparation, the E-PRF scaffold assayed via ELISA quantification assay as described above to determine the release (if any) of intrinsic BMP-2 from the platelet concentrate scaffold.
Study: NCT06475742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenerimod
Description: Film-coated tablets at a dose of 4 mg.
Study: NCT06450366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide Decanoate
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bempedoic Acid
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bempedoic Acid
Description: Administered orally.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Enlicitide Decanoate
Description: Administered orally.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Enlicitide Decanoate
Description: Administered orally.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Enlicitide Decanoate
Description: Administered orally.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Ezetimibe
Description: Administered orally.
Study: NCT06091436

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RecFSH / Follitropin alfa (Days 8 to hCG)
Description: From Stimulation Day 8 onwards a daily SC dose 75IU～300 IU recFSH was administered up to and including the Day of hCG.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RecFSH / Follitropin alfa (Days 8 to hCG)
Description: From Stimulation Day 8 onwards a daily SC dose 75IU～300 IU recFSH was administered up to and including the Day of hCG.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix
Description: On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganirelix
Description: On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hCG
Description: When 3 follicles \>= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hCG
Description: When 3 follicles \>= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 400 mg/day vaginally, and 40mg/d oral, which continued for at least 6 weeks, or up to menses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 400 mg/day vaginally, and 40mg/d oral, which continued for at least 6 weeks, or up to menses.
Study: NCT05993403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intercultural Sensitivity Education Program
Description: The training program consists of three sessions. In the Intercultural Sensitivity training for nurses, it was aimed to develop the level of intercultural sensitivity, and it was aimed to provide proficiency in providing services to raise awareness and knowledge about intercultural sensitivity.
Study: NCT05201768

Intervention type: OTHER
Intervention: balance tests,questionnaire
Description: Individuals will be tested and recorded.

Intervention type: OTHER
Intervention: balance tests,questionnaire
Description: Individuals will be tested and recorded.
Study: NCT06607965

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein and Carbohydrates
Description: Experimental Group:~6 hours before surgery, patients orally consumed 250 ml of a full-nutrition liquid (220 ml homogenized diet, 50 g; containing 31.4 g carbohydrates, 8 g protein, and 215 kcal).~2 hours before surgery, patients orally consumed 200 ml of a clear liquid (50 g enzymatically hydrolyzed rice powder + 0.5 g low-sodium salt; containing 47.7 g carbohydrates, 6.5 g whey protein, and 193 kcal).~After surgery, once there were no symptoms such as dizziness or vomiting, patients could start consuming clear liquids (containing 47.7 g carbohydrates, 6.5 g protein, and 221 kcal) orally every 30 minutes, 4 times on the day of surgery.~Starting from the first day after surgery, patients consumed 200 ml of fat-free nutritional liquid (50 g enzymatically hydrolyzed rice powder + 7.5 g isolated whey protein + 0.5 g low-sodium salt; 223 kcal) per serving, 4 to 6 times per day as needed.